GM-CSF worsens the outcomes in EAE and arthritis, whereas it improves the inflammation in Crohn’s disease, Type-1 diabetes, and Mysthenia gravis [26–29]. This evidence concerns the gene CSF2 and type 1 diabetes mellitus.